Molecular Mechanisms of Chemoresistance in Common Cancers Among Indian Patients
Cancer remains a major health challenge in India. Many patients show resistance to chemotherapy over time. Researchers now focus on molecular mechanisms behind this chemoresistance. They use advanced proteomic and transcriptomic analysis to uncover key reasons.
Scientists collect tumour samples from Indian patients with common cancers. These include breast, lung, colorectal, and oral cancers. Moreover, they compare tissues from responders and non-responders to treatment. As a result, they identify distinct molecular signatures.
Key Findings from Proteomic Analysis
Proteomic studies reveal changes in protein expression. Cancer cells often overexpress specific proteins that pump out chemotherapy drugs. Additionally, proteins involved in DNA repair become more active. Consequently, tumour cells survive treatment more effectively.
Researchers also notice alterations in cell survival pathways. For example, PI3K/AKT and MAPK pathways show increased activity in resistant cases. Furthermore, stress response proteins help cancer cells adapt to drug pressure. These changes explain why standard treatments lose effectiveness in many Indian patients.
Insights from Transcriptomic Analysis
Transcriptomic profiling examines gene expression patterns. It shows upregulation of genes linked to drug efflux and anti-apoptotic functions. Moreover, researchers detect epithelial-to-mesenchymal transition (EMT) markers. This transition makes cancer cells more aggressive and harder to treat.
Indian-specific factors appear important. Genetic variations common in local populations influence these pathways. Therefore, environmental and lifestyle elements further modify gene expression. As a result, chemoresistance patterns differ from Western countries.
Integrated Multi-Omics Approach
Scientists combine proteomic and transcriptomic data for deeper understanding. This integration highlights central regulatory networks. Additionally, bioinformatics tools help validate key targets. Consequently, they discover potential biomarkers for early detection of resistance.
Some patients carry mutations that activate alternative survival routes. Others show changes in microRNA regulation. Furthermore, tumour microenvironment interactions support resistant clones. These complex interactions demand personalised treatment strategies.
Implications for Indian Healthcare
This research opens new avenues for precision oncology. Doctors can use identified biomarkers to predict treatment response. Moreover, targeting specific molecular pathways may overcome resistance. As a result, patients receive more effective therapies with fewer side effects.
Researchers recommend larger cohort studies across different regions of India. They also suggest developing cost-effective diagnostic kits. Consequently, more patients can benefit from tailored cancer care.
Overall, proteomic and transcriptomic analyses provide valuable insights. They advance our understanding of chemoresistance in Indian cancer patients. Continued research in this direction promises better outcomes and improved survival rates.
CMP Bio World 